Clinical Trial

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-09-18; most recent amendment 2025-04-29.
Status change: Recruiting → Active, Not Recruiting 2025-04-29
Status change: Not Yet Recruiting → Recruiting 2023-10-02
Trial Details
NCT Number NCT06046820
Lead Sponsor Inozyme Pharma
Conditions Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Enrollment 27 participants
Start Date 2023-11-05
Primary Completion 2026-01 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-05-01